2. Search Result
Search Result
Results for "

Homologous domain

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

4

Biochemical Assay Reagents

1

Inhibitory Antibodies

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0842
    Bovine Serum Albumin
    50+ Cited Publications

    Albumin bovine serum; BSA

    		 Biochemical Assay Reagents Inflammation/Immunology
    Bovine Serum Albumin (BSA) is a 583-residue protein consisting of three homologous all-α domains, organized in a heart-shaped structure. BSA is a globular protein that is used in numerous biochemical applications.
    Bovine Serum Albumin
  • HY-D0842A
    Bovine Serum Albumin (Low Endotoxin,Fatty acid free)

    Albumin bovine serum (Low Endotoxin,Fatty acid free); BSA (Low Endotoxin,Fatty acid free)

    		 Biochemical Assay Reagents Nucleoside Antimetabolite/Analog Inflammation/Immunology
    Bovine Serum Albumin (Low Endotoxin,Fatty acid free) (BSA) is a 583 amino acid globular protein and oligonucleotide binding protein composed of three homologous full α domains. Bovine Serum Albumin (Low Endotoxin,Fatty acid free) (BSA) blocks the overall binding of oligonucleotides to cells. Bovine Serum Albumin (Low Endotoxin,Fatty acid free) (BSA) regulates the development of hamster embryos and induces arthritis .
    Bovine Serum Albumin (Low Endotoxin,Fatty acid free)
  • HY-18975
    I-BRD9
    5+ Cited Publications

    		 Epigenetic Reader Domain Inflammation/Immunology Cancer
    I-BRD9 is a selective cellular chemical probe of bromodomain-containing protein 9 (BRD9) with pIC50 value of 7.3 μM. I-BRD9 has high selectivity for bromodomain and extra terminal domain (BET) family and highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 can be used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways .
    I-BRD9
  • HY-CP002
    Bovine Serum Albumin, Carrier Protein

    		Biochemical Assay Reagents Others
    Bovine Serum Albumin (BSA) is a 583 amino acid protein consisting of three homologous full alpha structural domains. BSA is a spherical protein essential for the transport of molecules such as fatty acids, drugs and hormones from the blood. It is used in many biochemical applications as a drug carrier for biologically active compounds. For long-term storage, recombinant protein solution should be diluted further with 0.1% BSA .
    Bovine Serum Albumin, Carrier Protein
  • HY-174374
    Topobexin

    		Topoisomerase Cardiovascular Disease
    Topobexin is a TOP2B-selective inhibitor with IC50 values of 0.19 μM and 4.8 μM for TOP2B and TOP2A (DNA decatenation assay). Topobexin binds to non-homologous residues in the obex pocket and targets the ATPase domain of TOP2B. Topobexin prevents anthracycline-induced DNA double-strand break formation, apoptotic signaling mediated by caspase 3/7, 8 and 9, cardiomyocyte morphological changes, mitochondrial depolarization/loss, left ventricular systolic dysfunction, extracellular matrix remodeling, fibrotic alterations, and increases in plasma cardiac troponin T and BNP. Topobexin does not impair the antiproliferative effects of anthracyclines in cancer cells, exhibits no intrinsic cytotoxicity in cardiomyocytes, and is well tolerated in rabbits. Topobexin can be used in studies related to anthracycline-induced cardiotoxicity .
    Topobexin
  • HY-145685
    RECQL5-IN-1

    		DNA/RNA Synthesis Cancer
    RECQL5-IN-1 (Compound 4a) acts as an orally effective RECQL5 inhibitor (targeting both enzymatic and nonenzymatic domain). RECQL5-IN-1 is a potent inhibitor of RECQL5 helicase activity (IC50=46.3 nM), stabilizes the interaction between RECQL5-RAD51 proteins, causes RAD51 aggregation and homologous recombination repair (HRR) inhibition, thereby exhibiting selective cytotoxicity in RECQL5-expressing cancer cells .
    RECQL5-IN-1
  • HY-134258
    MEISi-1

    		HOXA Cardiovascular Disease Others Cancer
    MEISi-1 is a homeodomain inhibitor of small molecule MEIS1 protein. MEISi-1 significantly inhibited the activity of luciferase reporter genes containing MEIS binding sites (TGACAG) and induced self-renewal of mouse and human HSCS in vitro and in vivo. MEISi-1 can be used for research in blood diseases, heart regeneration and cancer .
    MEISi-1
  • HY-W023758
    HDGFRP2/PSIP1-IN-1

    4-(4-Bromo-1H-pyrazol-5-yl)pyridine

    		 DNA/RNA Synthesis Cancer
    HDGFRP2/PSIP1-IN-1 (compound BPP) is a dual inhibitor targeting the PWWP domain of hepatocarcinogenic growth factor-related protein 2 (HDGFRP2) and its homologous protein PSIP1, hinder the development and progression of diffuse intrinsic pontine glioma (DIPG). HDGFRP2/PSIP1-IN-1 binds to HDGFRP2 with a Kd value of 7 μM and a ligand efficiency of 0.47; it binds to the PSIP1 PWWP domain with a Kd value of 27 μM; meanwhile, it has a Kd value of 14 μM for HDGFRP3, indicating its effectiveness as an inhibitor of the HDGFRP2 PWWP subfamily .
    HDGFRP2/PSIP1-IN-1
  • HY-124846
    MI-223

    		Bcl-2 Family Cancer
    MI-223 is a Mcl-1 regulator (Kd = 160 nM). MI-223 binds to the BH1 domain, blocking Mcl-1-stimulated homologous recombination DNA repair, thus sensitizing cancer cells to DNA replication agents. MI-223 can be used in research on cancers such as lung cancer .
    MI-223
  • HY-149489
    JH-131e-153

    		PKC Neurological Disease
    JH-131e-153, a diacylglycerol (DAG)-lactone, is a small molecule activator of Munc13-1, targeting the C1 domain. The activation sequence of JH-131e-153 on Munc13-1 is WT>I590≈R592A≈W588A. The C1 domain of Munc13-1 and protein kinase C (PKC) are homologous in sequence and structure. The activation sequence of JH-131e-153 on Munc13-1 and PKC was PKCα>Munc13-1>PKCε. JH-131e-153 regulates neuronal processes through Munc13-1 and can be further used in the study of neurodegenerative diseases .
    JH-131e-153
  • HY-NP185
    Chicken Tenascin,suitable for cell culture

    		Biochemical Assay Reagents Others
    Chicken Tenascin,suitable for cell culture is a glycoprotein that forms disulfide-linked hexamers. Chicken Tenascin,suitable for cell culture is composed of repetitive domains, including EGF-like repeats, fibronectin type III repeats, and a region homologous to fibrinogen. Chicken Tenascin,suitable for cell culture can be used for cell culture .
    Chicken Tenascin,suitable for cell culture
  • HY-P992365
    HFB101110

    		CCR Cancer
    HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
    HFB101110
  • HY-181557
    SY-589

    		DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Cancer
    SY-589 is an orally active DNA polymerase Polθ helicase domain inhibitor (IC50=2.29 nM) and DNA damage inducer. SY-589 inhibits the ATPase activity of the Polθ helicase domain and blocks the Polθ-mediated microhomology-mediated end joining (MMEJ) DNA repair pathway (IC50=0.85 nM). SY-589 also induces the accumulation of DNA double-strand breaks by increasing γ-H2AX levels. SY-589 exerts antiproliferative effects on BRCA2-deficient cells and is used in the research of HR-deficient tumors .
    SY-589
  • HY-185459
    PCIP-1

    		PARP Epigenetic Reader Domain Cancer
    PCIP-1 is a PARP2 inhibitor. PCIP-1 recruits BET proteins to PARP2 to inhibit DNA repair, acts via event-driven pharmacology, and does not inhibit PARP-catalyzed PARylation. PCIP-1 inhibits DNA repair, thereby inducing synthetic lethality in homologous recombination-deficient cancer cells and increasing the sensitivity of PARP1-knockout cells. PCIP-1 can be used in the research of homologous recombination-deficient cancers, T-cell acute lymphoblastic leukemia, and BRCA-mutant cancers .
    PCIP-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: